![]() (you can Read the full research report on Pfizer here >,Ĭitigroup Shares have underperformed Jacques Banks – the major sectoral industry – compared to last year (-41.2% versus -29.1%). Pfizer has a good record of surprising earnings in recent quarters Estimates remain stable ahead of third quarter earnings. Our estimates for Pfizer’s top line suggest a CAGR decline of approximately 30% over the next three years. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure. However, currency headwinds and pricing pressure are major top-line headwinds. Pfizer boasts a sustainable pipeline with several late-stage programs that can accelerate growth. Its COVID-19 vaccine, together with the oral antiviral pill, Paxlovid, is expected to generate a combined $54 billion in sales in 2022. The company currently stands firmly in the COVID Vaccine/Treatment market. Of pfizer Shares have gained +0.6% over the previous year, against a gain of +5.6% for the Jacques Large Cap Pharmaceuticals Industry. (you can Read the full research report on NVIDIA here >, ![]() Additionally, collaborations with the likes of Mercedes-Benz and Audi are expected to further strengthen NVIDIA’s presence in the autonomous vehicles and other automotive electronics space. However, solid use of smart cockpit infotainment solutions based on artificial intelligence is likely to aid NVIDIA’s growth.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |